microdosing tirzepatide maintenance Micro-dosing is about more than just weight loss: it's about supporting your body's natural balance. By targeting visceral fat, calming inflammation, and improving energy and focus, many are finding it helps Women's Microdosing & Weight Maintenance

Wegovy is a GLP-1 receptor agonist licensed in the UK for chronic weight management in adults with obesity or overweight with comorbidities, whilst Adderallan amphetamine-based stimulantis not licensed in the UK

Fight Off Hunger Pangs and Achieve Sustainable (and Dramatic) Weight Loss Originally developed to manage type 2 diabetes, Tirzepatide is a dual GLP-1 and GIP receptor agonist that has shown remarkable effectiveness in promoting weight loss

Managing Side Effects During Tirzepatide Dose Increases Nausea, vomiting, constipation, and reduced appetite are common during the first 2 to 4 weeks after each dose increase, though most side effects resolve within days as your body acclimates

Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from single agonists (Semaglutide) and dual agonists (Tirzepatide)